Navigation Links
Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for Its Revolutionary, Patented Symphony(TM) tCGM System
Date:2/18/2010

FRANKLIN, Mass., Feb. 18 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced today that the Company has made a significant advance in the product design of its Symphony tCGM device and that it has developed its next generation electronic component package. This important advance includes an initial 33% reduction in component size and improved architectural design as compared to the prototype electronic package of the Company's earlier Symphony tCGM device. The Company also announced today that it expects to complete the product development work for the entire Symphony tCGM System in the near-term and that it anticipates entering new clinical trials shortly thereafter.

The completion of this electronic component package represents a major step towards custom integrated circuitry and product development completion. The Company believes that this accomplishment, coupled with the previously announced, improved, one-piece biosensor that utilizes new materials and an improved geometrical design, will improve sensor performance and significantly decrease the size of the tCGM device from the size of the original prototype. The final Symphony tCGM device is intended to be a cost-effective product that allows for advanced continuous glucose monitoring for patients and healthcare providers.

"The completion of this critical step in the product development program for Symphony demonstrates the Company's steadfast commitment to rapidly developing the world's most advanced solution for needle-free, continuous glucose monitoring technology," stated Patrick T. Mooney, M.D., Chairman and CEO of
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
(Date:3/31/2015)... , March 31, 2015  CVS Health (NYSE: ... into new clinical affiliations with Rush University Medical ... and Tucson Medical Center in Tucson, ... Arizona Connected Care. These affiliations will help enhance ... patients. Through these clinical affiliations, CVS Health will ...
(Date:3/31/2015)... , March 31, 2015  Oxis International, Inc. (OXIS) ... development and commercialization, announced today Oxis CEO Tony ... of Oxis common shares on the Euronext exchange. Oxis ... the symbol OXIS.   Oxis Chairman and ... to move forward with its strategies launched in 2014 ...
Breaking Medicine Technology:Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2
... Mich., and GERMANTOWN, Md., Nov. 21, 2011 Adeona ... a developer of innovative disease-modifying medicines for serious ... Corporation, a synthetic biology company that utilizes its ... announced today the formation of a global exclusive ...
... 18, 2011 Breast cancer patients, their families and ... Administration (FDA) decision to remove the anti-cancer drug Avastin ... stage breast cancer. Terry Kalley, founder of ... condemned the decision, saying, "While this vote is highly ...
Cached Medicine Technology:Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 2Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 3Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 4Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 5Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 6Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 7
(Date:3/31/2015)... 2015 OnChip Devices , a world ... silicon ESD diode chip targeted towards low voltage LED applications. ... Zeners are ideal for protecting circuits by suppressing voltage higher ... handle pulses of up to 350W and 20A, providing protection ... 61000-4-2 standard. These diodes do not exhibit any device ...
(Date:3/31/2015)... Clinovo, a leading provider of cloud-based ... the premiere voice of Northern California’s Life Science ... , BayBio brings together the collective strength ... productive life science cluster, helping companies grow, connect ... pressing challenges. , “We are thrilled to ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 At Summit Breast ... all patients in a calm and caring manner. , Summit ... diagnosis and surgical treatment of breast cancer. They treat ... but from all over the world. Their doctors continue ... publications. , The seeds for Summit Breast Care were planted ...
(Date:3/31/2015)... 2015 Beckman Coulter is sponsoring a ... “Subvisible Particulate Matter in Therapeutic Protein Injections”,” an educational session ... in counting particles in liquids, with a focus on the ... free to attend and will be broadcast live April 8, ... new test for protein-based materials, known as USP 787 ...
(Date:3/31/2015)... 31, 2015 BESLER Consulting today ... “The Value of an Independent Cost Report Review.” ... a critical role in the determination of Medicare ... appropriate understanding and review, this report can assist ... planning. , This white paper discusses:, ...
Breaking Medicine News(10 mins):Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 3
... Those with high levels of Epstein-Barr antibodies double their ... 7 (HealthDay News) -- Smoking appears to enhance the ... nearly doubling the chances of getting the disabling neurologic ... risk factor is having high levels of antibodies to ...
... Studying patients with kidney cancer, a team of researchers at ... a pair of proteins excreted in the urine that could ... The research, published online in the May issue of ... proteins secreted in urine that appear to accurately reveal the ...
... Henry Ford Hospital have found that infection with the ... cancer. Using administrative data from more than 67,000 ... the period 1997-2008, 0.6% (17/3057) patients with hepatitis C ... without the disease developed kidney cancer. After ...
... insight into patterns, coloring for species generally , WEDNESDAY, ... learned the long-sought-after secret of how animals make spots, ... a species of fruit fly ( Drosophila guttifera ) ... spots. Researchers found that morphogen -- a protein present ...
... drug might reverse genetic process that leads to disease, ... Researchers may have found an easy way to detect ... as well as a way to reverse the start ... drug. , "It,s incredibly, incredibly exciting," said Dr. ...
... levels of copper and iron to Alzheimer,s disease, heart disease, ... Chemical Research in Toxicology suggests specific steps that older ... of these metals in their bodies. "This story of copper ... of public health significance, is virtually unknown to the general ...
Cached Medicine News:Health News:Smoking May Boost MS Risk in Some 2Health News:Smoking May Boost MS Risk in Some 3Health News:Urine test for kidney cancer a step closer to development 2Health News:Urine test for kidney cancer a step closer to development 3Health News:Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer 2Health News:Science Reveals Secrets of Animals' Spots, Stripes 2Health News:Simple Test May Spot Early Lung Cancer 2Health News:Simple Test May Spot Early Lung Cancer 3
Inquire...
... the elegant and sophisticated woman, ... includes ophthalmic and sunwear styles. ... variety of shapes and colors, ... shapes and complexions. Many styles ...
... updated styling through the use of innovative ... collection is for the value driven consumer ... Eyewear Collection , The futuristic quality ... of the "strongest and lightest metal on ...
Inquire...
Medicine Products: